NT-I7 is a Unique T Cell Amplifier.

Interleukin-7 (IL-7) is Central to T Lymphocyte Development and Survival.
IL-7 plays a key role in T cell development and survival1,2. When T cell numbers are low, the physiological level of IL-7 increases to stimulate T cell expansion. However, as a homeostatic cytokine, IL-7 levels do not rise dramatically in these settings, and recovery of T cell numbers is often a slow process3.

IL-7 acts through IL-7 receptor (IL-7R), which is expressed on naïve and memory CD4+ and CD8+ T cells. Thus, IL-7 promotes proliferation, maintenance, and functionality of these key T cell subsets mediating immune responses. On the other hand, IL-7R is expressed on regulatory T cells at low levels, which is a T cell subset involved in limiting T cell responses4.

At NeoImmuneTech, we are exploring the utility of IL-7 based therapeutics in enhancing immune function.
NT-I7 is a More Potent, Stable, and Long-Acting Human IL-7.
NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. The IL-7 domain promotes T cell development which plays a central role in immune response. The N-terminus of the IL-7 domain was engineered to overcome its structural instability and to enable mass production of NT-I7. The hyFc® domain extends the half-life of IL-7, thereby enhancing bioavailability which provides better potency and stability.
NT-I7 Boosts T Cell Numbers and Functionality to Enhance Immune Function and Potentially Provide Greater Therapeutic Benefits to Patients.

1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.